MarketCapExport financials
Akero Therapeutics (AKRO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Akero Therapeutics Balance Sheet 2024-2011 | AKRO
Brief balance sheet overview of Akero Therapeutics
The balance sheet is assessed across five available annual reports spanning 2020 to 2024.
Assets rose from $273.3 million to $825.9 million, a gain of +202.1%, while CAGR was about 31.8%. The balance sheet expanded rapidly.
Asset growth of +202.1% came with a +418% rise in liabilities. Financial leverage became more prominent.
The equity-to-assets ratio is 90.8%, compared with 94.6% five periods ago. The balance sheet has a substantial internal cushion.
The balance sheet holds more cash than interest-bearing debt; net debt is -$339.7 million, indicating minimal leverage.
Cash accounts for 41.2% of assets versus 68.5% initially. The change indicates the degree of financial flexibility.
Retained earnings remain negative at -$826.2 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Conclusion
Akero Therapeutics's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.
Annual Balance Sheet Akero Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-340 M | -233 M | -249 M | -149 M | -184 M | -64.8 M | -76 M | -598 K | - | - | - | - | - | - |
Long Term Debt |
529 K | 819 K | 1.08 M | 1.31 M | 1.52 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 1.52 M | 23 K | 125 M | 5 M | - | - | - | - | - | - |
Total Current Liabilities |
39.8 M | 19.1 M | 19.1 M | 25.1 M | 13.1 M | 9.37 M | - | - | - | - | - | - | - | - |
Total Liabilities |
75.8 M | 45 M | 30 M | 26.4 M | 14.6 M | 9.39 M | 127 M | 5.22 M | - | - | - | - | - | - |
Retained Earnings |
-826 M | -574 M | -422 M | -310 M | -210 M | -130 M | -86.6 M | -4.56 M | - | - | - | - | - | - |
Total Assets |
826 M | 580 M | 357 M | 196 M | 273 M | 138 M | 77.2 M | 658 K | - | - | - | - | - | - |
Cash and Cash Equivalents |
340 M | 234 M | 250 M | 151 M | 187 M | 64.8 M | 76 M | - | - | - | - | - | - | - |
Book Value |
750 M | 535 M | 327 M | 169 M | 259 M | 129 M | -49.9 M | -4.56 M | - | - | - | - | - | - |
Total Shareholders Equity |
750 M | 535 M | 327 M | 169 M | 259 M | 129 M | -49.9 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Akero Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
289 K | 372 K | 451 K | 529 K | 605 K | 679 K | 750 K | 819 K | 888 K | - | 1.02 M | 1.08 M | 1.14 M | - | 1.26 M | 1.31 M | 1.36 M | 1.42 M | 1.47 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
47.9 M | 83.3 M | 72 M | 75.8 M | 79.2 M | 67 M | 66 M | 45 M | 52.2 M | - | 42.5 M | 30 M | 35.9 M | - | 23.4 M | 26.4 M | 24.9 M | 17.9 M | 11.6 M | 14.6 M | 14.6 M | 14.6 M | 14.6 M | 9.39 M | 9.39 M | 9.39 M | 9.39 M | 2.34 M | 2.34 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.05 B | -967 M | -897 M | -826 M | -756 M | -683 M | -627 M | -574 M | -519 M | - | -448 M | -422 M | -399 M | - | -336 M | -310 M | -278 M | -254 M | -225 M | -210 M | -210 M | -210 M | -210 M | -130 M | -130 M | -130 M | -130 M | -86.6 M | -86.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.01 B | 1.11 B | 1.16 B | 826 M | 818 M | 865 M | 912 M | 580 M | 635 M | - | 349 M | 357 M | 379 M | - | 170 M | 196 M | 224 M | 238 M | 258 M | 273 M | 273 M | 273 M | 273 M | 138 M | 138 M | 138 M | 138 M | 77.2 M | 77.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
176 M | 220 M | 186 M | 340 M | 316 M | 310 M | 624 M | 234 M | 270 M | 444 M | 258 M | 250 M | 374 M | - | 151 M | 150 M | 165 M | 158 M | 188 M | 187 M | 187 M | 187 M | 187 M | 64.8 M | 64.8 M | 64.8 M | 64.8 M | 76 M | 76 M | 9.81 M | - | 618 K | - | 618 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
958 M | 1.03 B | 1.08 B | 750 M | 738 M | 798 M | 846 M | 535 M | 583 M | - | 306 M | 327 M | 344 M | - | 147 M | 169 M | 199 M | 220 M | 246 M | 259 M | 259 M | 259 M | 259 M | 129 M | 129 M | 129 M | 129 M | 74.8 M | 74.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
958 M | 1.03 B | 1.08 B | 750 M | 738 M | 798 M | 846 M | 535 M | 583 M | 616 M | 306 M | 327 M | 344 M | 148 M | 147 M | 169 M | 199 M | 220 M | 246 M | 259 M | 259 M | 259 M | 259 M | 129 M | 129 M | 129 M | 129 M | -49.9 M | -49.9 M | -13.7 M | -4.98 M | -4.56 M | - | -4.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Akero Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
USA
Russia
Niderland
France
Israel
Australia
Danmark
